1. Introduction
===============

Acute respiratory tract infections are the most common reason for general practitioner visits and acute admission to hospital during the winter season irrespective of age or gender ([@bib8]). In 2002, lower respiratory tract infections accounted for 3.9 million deaths worldwide; 6.9% of all deaths that year ([@bib30]). Viral and bacterial co-infections are frequently observed using PCR-based investigation, which in many cases are not detected by current serological-based and direct antigen detection methods. Therefore, the development of new diagnostic methods is required to enable the detection of a broad range of pathogens. Indeed an accurate, sensitive and rapid differential diagnosis can influence patient management, reduce potentially inappropriate antibiotic use and aid infection control measures in institutional settings.

The current serological-based methods for the diagnosis of acute respiratory tract infections are limited in assay specificity and sensitivity, often resulting in underdiagnosis, e.g. antigen detection of the *Adenoviridae* ([@bib1]). However, viral antigen detection tests are used increasingly because of low demand on equipment and cost effectiveness ([@bib9]). In addition, virus isolation is slow, expensive and labour intensive; often requiring 1--5 days incubation to detect or confirm the absence of cytopathic effects. In addition, with decreasing resources fewer clinical laboratories have the appropriate facilities and expertise to undertake culture-based investigations ([@bib15]). Culture-based methods are also used for bacterial detection and are also hampered by slow turnaround times for reporting of results and insufficient sensitivity ([@bib24]). Serological profiling is also used often, however, this can require more than two weeks for antibodies to develop and sequential samples, which are often not collected and are usually required to confirm the diagnosis ([@bib23], [@bib31]).

Advances in molecular diagnostic methods have enabled rapid diagnosis of infectious disease ([@bib21]). Molecular techniques offer several advantages over conventional serology-based methods, including speed, ease of standardisation, automation and high assay sensitivities and specificities ([@bib6]). To date, DNA microarray technology has been used predominantly for gene expression profiling studies in basic research applications ([@bib13]). Clinical presentations of acute respiratory tract infections are diverse and non-specific; therefore an efficient laboratory assay that can detect a panel of common respiratory pathogens would be advantageous. In addition, large-scale screening may identify co-infections, which would not have been detected previously. Microarray-based analysis is a cost-effective approach that yields reproducible results and can allow replicate analyses in a single assay run. This is achieved by spotting of solid phase arrays with multiple copies of the same probe, alternative probes within the same target amplicon and/or mismatch probes allowing intra-assay confirmation of results that is not readily possible with multiplex rtPCR-based approaches.

A novel, non-fluorescent, low-cost, low density oligonucleotide microarray format has been developed which facilitates the use of DNA microarrays for clinical diagnostic purposes. The ArrayTube™ (AT) platform offers a fully automated system for clinical diagnosis. Several studies have used this platform for a variety of applications ([@bib2], [@bib25], [@bib26]). The AT system represents a cost-effective platform involving 2.4 mm × 2.4 mm glass biochips, integrated into the bottom of standard 1.5 ml plastic microtubes. The chip may contain a number of different probe types depending on the specific application and allows all steps of the hybridisation reaction to be conducted within the AT vessel, obviating the requirement for a separate hybridisation chamber or other additional laboratory equipment. The hybridised target is visualised by enzyme-catalysed precipitation and the microtubes are read using a simple low cost, transmission scanner. A previous study revealed that specific hybridisation to virus-specific oligonucleotide probes can be obtained from a single PCR amplifiable target copy ([@bib7]).

The development of an oligonucleotide microarray-based system for the detection, differentiation and subtyping of 18 viral and bacterial respiratory pathogens simultaneously, comprising 16 viruses and two atypical bacteria is described. PCR-derived amplicons from external quality assessment panels and known positive samples were used as targets to establish probe sensitivity. A validation panel was assembled, comprised of throat swab specimens, collected from adults who presented with symptoms of respiratory disease to a tertiary care hospital during the 2007--2008 winter season, to evaluate the potential role of the microarray assay compared to multiplex rtPCRs.

2. Materials and methods
========================

2.1. Oligonucleotide probe selection
------------------------------------

Oligonucleotide probe genomic target regions are listed in [Table 1](#tbl1){ref-type="table"} . Oligonucleotide probes were evaluated using Primer3 (<http://frodo.wi.mit.edu/>). Probes on the array were between 18 and 35 nucleotide bases in length and were modifications of existing TaqMan assays. The most important parameter for modification of existing published TaqMan probes was that they would have similar *T* ~m~ values so that hybridisation would be uniform for all denatured amplicons on the array. All probes have a *T* ~m~ value close to the average of all probes and *T* ~m~ values were calculated using Primer3 which uses the SantaLucia method for *T* ~m~ calculation ([@bib27]). The 18 pathogens included Adenoviruses, Bocavirus, *Chlamydia* (*Chlamydophila*) *pneumoniae*, Coronaviruses types 229E, OC43, NL63, HKU1, Human metapneumovirus (hMPV) types A and B, Influenza A, Influenza B, Influenza C, *Mycoplasma pneumoniae*, Parainfluenza viruses 1--4, respiratory syncytial virus (RSV) types A and B and Rhinoviruses.Table 1Oligonucleotide probe sequence and genomic target region information.Oligonucleotide probe nameGenomic regionProbe sequenceOligonucleotide probe nameGenomic region80Probe sequenceAdenovirus-01[a](#tbl1fn1){ref-type="table-fn"}Hexon geneAGACCCGGGCTCAGGTACTCCInfluenza B-01NS geneATGGCCATCGGATCCTCAACTCACTCTAdenovirus-05[a](#tbl1fn1){ref-type="table-fn"}Hexon geneGGCTGAAGTACGTCTCGGTGGCInfluenza B-02NS geneATGGCCATCGGATCCTCAATTCACTCTAdenovirus-06[a](#tbl1fn1){ref-type="table-fn"}Hexon geneCCCGGGCTCAGGTACTCCGAGInfluenza CMatrixCTCTTCCTTCTGATTTTTTCAAAGCAACTTCTAGTTTGAAAAAATCAGAAGGAAGAGAAdenovirus-07[a](#tbl1fn1){ref-type="table-fn"}Hexon geneCAGGCTGAAGTACGTATCGGTGGCParainfluenzavirus1-01HNCCTATGACATCAACGACAACAGGAAATCATGAdenovirus-09[a](#tbl1fn1){ref-type="table-fn"}Hexon geneTGAAGTAGGTGTCTGTGGCGCGParainfluenzavirus-2HNACCTAAGTGATGGAATCAATCGCAAAAGCAdenovirus-10[a](#tbl1fn1){ref-type="table-fn"}Hexon geneTGAAGTAGGTGTCTGTTGCACGGGParainfluenzavirus-3-01HNTGGATGTTCAAGACCTCCATACCCGABocavirus[b](#tbl1fn2){ref-type="table-fn"}Non-capsid protein 1AGCTCAGGGAATATGAAAGACAAGCATCGParainfluenzavirus-3-02HNTGGATGTTCAAGACCTCCATATCCGAGEnterovirus-01[c](#tbl1fn3){ref-type="table-fn"}5′ NCRCCCAAAGCCACGGGACGCTAGParainfluenzavirus-3-03HNTGGGTGTTCAAGACCTCCATATCCGAEnterovirus-2[c](#tbl1fn3){ref-type="table-fn"}5′ NCRGCCCAAAGCCACAGGACGCTAGParainfluenza-4FusionCCMATCACAAGCTCAGAAATYCAAAGTCGThMPV-A[d](#tbl1fn4){ref-type="table-fn"}FusionCAACATTTAGAAACCTTCTGTTGAATTGACTGAAGRespiratory syncytial virus A[f](#tbl1fn6){ref-type="table-fn"}NPCACCATCCAACGGAGCACAGGAGAThMPV-B[d](#tbl1fn4){ref-type="table-fn"}FusionCTGCCGCACAACATTTAGGAATCTTCTGRespiratory syncytial virus B[f](#tbl1fn6){ref-type="table-fn"}NPTGCTATGTCCAGGTTAGGAAGGGAAGAC  Human coronavirus 229E[e](#tbl1fn5){ref-type="table-fn"}NPCCCTGACGACCACGTTGTGGTTCRhinovirus-01[g](#tbl1fn7){ref-type="table-fn"}5′ NCRTCCTCCGGCCCCTGAATGCGRhinovirus-02[g](#tbl1fn7){ref-type="table-fn"}TCCTCCGGCCCCTGAATGTG  Human coronavirus NL63[e](#tbl1fn5){ref-type="table-fn"}NPATTGCCAAGGCTCCTAAACGTACAGGTRhinovirus-03[g](#tbl1fn7){ref-type="table-fn"}5′ NCRGGACAGGGTGTGAAGAGCCGCRhinovirus-04[g](#tbl1fn7){ref-type="table-fn"}GGACAGGGTGCGAAGAGCCG  Human coronavirus OC43[e](#tbl1fn5){ref-type="table-fn"}NPTTCCGCCTGGCACGGTACTCC*Chlamydophila pneumoniae*-0[h](#tbl1fn8){ref-type="table-fn"}omp ACTACTGGAACAAAGTCTGCGACCATHuman coronavirus HKU1-01[e](#tbl1fn5){ref-type="table-fn"}Replicase 1bTGTGTGGCGGTTGCTATTATGTTAAGCCT*Chlamydophila pneumoniae*-02[h](#tbl1fn8){ref-type="table-fn"}omp AAGCTACTGGAACAAAGTCTGCGACCAHuman coronavirus HKU1-02[e](#tbl1fn5){ref-type="table-fn"}Replicase 1bTGAAATAGTTATGTGTGGCGGTTGCTATTATGT*Mycoplasma pneumoniae*-01[h](#tbl1fn8){ref-type="table-fn"}p1 adhesionTCGGCCCCGATCGCCCTCInfluenza AMatrixACGCTCACCGTGCCCAGTG*Mycoplasma pneumoniae*-02[h](#tbl1fn8){ref-type="table-fn"}p1 adhesionCCAAGCAGGGCTTTCAAAAGGAAGCTK-*ras*-01Exon 1TGCCTACGCCACAAGCTCCAACTAC[^1][^2][^3][^4][^5][^6][^7][^8][^9]

2.2. DNA microarray production
------------------------------

Oligonucleotide probes (Metabion, Martinsried, Germany), ∼18--35 bp in length, were spotted in fourfold redundancy on glass arrays using a proprietary technology (ArrayTube, Clondiag Technologies, Jena, Germany).

2.3. Pathogen target labelling by end-point PCR
-----------------------------------------------

Biotinylation end-point PCR primer sequences and multiplex set-up are shown in [Table 2](#tbl2){ref-type="table"} . The OneStep RT-PCR kit (Qiagen, Crawley, UK) was used according to the manufacturing instructions with the modified addition of 0.15 mM dTTP and 0.2 mM dATP, dGTP, dCTP and 0.05 mM biotin-21-dUTP per reaction (Annecis Ltd., Lancaster, UK) for target labelling. PCR conditions were 1 cycle of 50 °C for 30 min, 1 cycle of 95 °C for 15 min, 50 cycles of 94 °C for 30 s, 55 °C for 1 min, 72 °C for 1 min and final extension for 1 cycle of 72 °C for 10 min on a PTC-200 thermocycler (MJ Research, Waltham, MA, USA).Table 2Multiplex biotinylation end-point PCR and rtPCR set-up.Multiplex PCRVirusForward primer (5′--3′)Reverser primer (5′--3′)Tube 1Influenza AAAGACAAGACCAATYCTGTCACCTCTTCTACGYTGCAGTCCYCGCTInfluenza BATGATCTTACAGTGGAGGATGAAGAACGAATTGGCTTTGRATGTCCTTInfluenza CGGCAAGCGACATGCTGAAYATCCAGCTGCYTTCATTTGCTTT  Tube 2Parainfluenza-2ATGAAAACCATTTACCTAAGTGATGGACCTCCYGGTATRGCAGTGACTGAACParainfluenza-3CCAGGGATATAYTAYAAAGGCAAAACCGGGRCACCCAGTTGTGParainfluenza-4CAGAYAACATCAATCGCCTTACAAAAGCAAYTGTACCTATGACTGCC  Tube 3hMPV-AGCYGTYAGCTTCAGTCAATTCAATCCAGCATTGTCTGAAAATTGChMPV-BGCYGTYAGCTTCAGTCAATTCAAGTTATCCCTGCATTGTCTGAAAACTParainfluenza-1GTGATTTAAACCCGGTAATTTCTCACCTTGTTCCTGCAGCTATTACAGA*Mycoplasma pneumoniae*CAGACGGTCGCGGATAACGAACCAGGTGAGGTTGCCAATG  Tube 4Coronavirus 229ECAGTCAAATGGGCTGATGCAAAAGGGCTATAAAGAGAATAAGGTATTCTCoronavirus OC43CGATGAGGCTATTCCGACTAGGTCCTTCCTGAGCCTTCAATATAGTAACCCoronavirus NL63ACGTACTTCTATTATGAAGCATGATATTAAAGCAGATCTAATGTTATACTTAAAACTACGCoronavirus HKU1TCGCCTTGCGAATGAATGTGCTTGCATCACCACTGCTAGTACCAC  Tube 5RSV-AAGATCAACTTCTGTCATCCAGCAATTCTGCACATCATAATTAGGAGRSV-BAAGATGCAAATCATAAATTCACAGGATGATATCCAGCATCTTTAAGTARhinovirusCPXGCCZGCGTGGCGAAACACGGACACCCAAAGTA  Tube 6AdenovirusGCCACGGTGGGGTTTCTAAACTTGCCCCAGTGGTCTTACATGCACATCBocavirusGCACAGCCACGTGACGAATGGACTCCCTTTTCTTTTGTAGGAK-rasGCCTGCTGAAAATGACTGAATATAAACTGATTCTGAATTAGCTGTATCGTCAAG*Chlamydophila pneumoniae*AGGCGTTGCTTTCCCCTTGCCGATAGAGAGGCTCCTACTTGCCAT[^10]

2.4. DNA microarray hybridisation
---------------------------------

The microarrays were washed in nuclease-free water (Promega, Madison, WI, USA) and hybridisation buffer \[250 mM NaPOi, pH 7.2 (Camida Ltd., Tipperary, Ireland); 4.5% SDS; 1 mM EDTA, pH 8.0; 1× SSC\] (Sigma, Dublin, Ireland) for 5 min each at 55 °C at 550 rpm in the Thermomixer comfort (Eppendorf AG, Hamburg, Germany). A 0.5 μl volume of each target solution in a final volume of 100 μl of hybridisation buffer was heated at 95 °C for 5 min and then chilled on ice. The biotinylated target reactions were hybridised to the microarrays at 55 °C for 1 h at 550 rpm. DNA arrays were washed in solutions of decreasing stringency \[2× SSC, 0.01% Triton X; 2× SSC; 0.2× SSC\] (Sigma, Dublin, Ireland) for 5 min each at 30 °C at 550 rpm. Blocking was performed using 2% BSA in 6XSSPE, 0.005% Triton X (Sigma, Dublin, Ireland) for 15 min at 30 °C at 550 rpm. A 1 in 5000 dilution of streptavidin-horseradish peroxidise (SA-HRP) conjugate (Pierce, Dublin, Ireland) was added for 15 min at 30 °C at 550 rpm. Washing was repeated in solutions of decreasing stringency \[2× SSC, 0.01% Triton X; 2× SSC; 0.2× SSC\] (Sigma, Dublin, Ireland) for 5 min each at 30 °C at 550 rpm to remove unbound SA-HRP conjugate. Visualisation of the hybridised targets was achieved by incubation with 100 μl tetramethyl bendzidine (TMB) (KPL Ltd., MD, USA) at 20 °C for 10 min.

2.5. DNA microarray data analysis
---------------------------------

Hybridisation signals were measured at 20 °C after 10 min using the ATR03 AT DNA microarray transmission scanner (Clondiag Technologies, Jena, Germany). Quantitative staining values (QSVs) with local background correction were obtained for each probe spot via the Iconoclust software, version 2.3 (Clondiag Technologies, Jena, Germany). The criteria for assignment of hybridisation patterns were as follows:

Background-corrected signal intensities were given as NI = 1--*M*/BG, with NI being Normalised Intensity, *M* is Mean spot intensity, and BG local background intensity. Spot intensities were measured as light transmission, with *M* values ranging from 1 for complete transmission (background, weak spots) to 0 for complete absorption (dark spots). Normalised intensities ranged between 0 and 1. QSVs were reported as the median of all four replicate signals for each probe.

2.6. Multiplex rtPCR analysis
-----------------------------

Real-time PCR primer sequences and multiplex set-up are shown in [Table 2](#tbl2){ref-type="table"} and carried out using the Invitrogen Superscript III one-step qPCR system according to the manufacturer\'s instructions (Invitrogen, Paisley, UK). For an internal control for the extraction efficiency, sample addition and the absence of PCR inhibitors in each specimen we amplified a human gene (k-ras) from all throat swabs.

2.7. PCR product preparation
----------------------------

Biotinylated PCR products were purified using the High Pure PCR product Purification Kit according to manufacturers instructions and eluted in 50 μl (Roche Applied Science, Mannheim, Germany). DNA concentration was determined using the NanoDrop ND-1000 spectrophotometer (Thermo Scientific, DE, USA) and all DNA target solutions normalised to 50 ng/μl. A series of 10-fold dilutions (5000--5 pg/μl) were prepared and subjected to DNA microarray analysis.

2.8. Specimen collection and nucleic acid extraction
----------------------------------------------------

Throat swabs were collected from adult patients with respiratory symptoms presenting at an emergency department in a tertiary care hospital in Dublin during the 2007--2008 winter season. Swabs were stored in viral transport medium at −80 °C before processing. DNA and RNA were extracted from respiratory specimens using the QIAamp Virus BioRobot MDx kit on the BioRobot MDx workstation, according to the manufacturer\'s instructions (Qiagen, Crawley, UK).

3. Results
==========

We have developed and validated a diagnostic PCR-based low density oligonucleotide microarray for the detection of 16 viral and 2 bacterial respiratory pathogens. In initial studies the oligonucleotide microarray probe specificity was assessed using known positive specimens (i.e. either external quality assessment samples or clinical material confirmed by rtPCR and/or sequencing) and then analytical sensitivity was evaluated by serial dilution of biotinylated target amplicons and hybridisation to the array. [Table 3](#tbl3){ref-type="table"} lists the QSVs for each of the individual pathogen probes, the mean internal staining controls, the background signal for the assay, the background signal for an equivalent 'negative' assay as well as the factor by which the signal is greater than the background level. Excluding Coronavirus OC43 which had a QSV of 0.55, the remaining probes exhibited QSVs between 0.62 and 0.95, with the median QSV being 0.77. All internal staining controls had a QSV of ≥0.84. The minimum factor by which the probe signal was greater than the background was a factor of 80 (coronavirus OC43) and the maximum was 529 (RSV subtype B). Certain pathogens that had multiple probes of differing sequences showed a greater specificity for a single probe sequence, e.g. Parainfluenza-3; 0.85, 0.81 and 0.73 for all 3 probes respectively. The analytical sensitivity of the microarray was evaluated using a serial dilution of individual targets of known concentration. The majority of the probes exhibited a reduced sensitivity below 50 pg of target DNA/cDNA and a complete loss of signal below 5 pg of target DNA for all probes (data not shown). Some signal was observed at 5 pg of target DNA for the probes RSV subtype A, Rhinovirus-03 and -04, with Rhinovirus-03 still yielding a QSV of approximately 0.63.Table 3Oligonucleotide microarray probe specificity.Oligonucleotide probeProbeBG (QSV)Signal-to-noise ratio (*x*factor)Negative control BG (QSV)Staining control (QSV)Influenza A0.72*x*198Influenza B[a](#tbl3fn1){ref-type="table-fn"}0.88, 0.920.00363*x*242, 2530.00200.84Influenza C[a](#tbl3fn1){ref-type="table-fn"}ntnt  Parainfluenza-20.86*x*500Parainfluenza-3[b](#tbl3fn2){ref-type="table-fn"}0.85, 0.81, 0.730.00172*x*494, *x*471, *x*4240.00070.87Parainfluenza-4nt--  hMPV-A0.69*x*191hMPV-B0.62*x*171Parainfluenza-10.90*x*2490.00010.85*Mycoplasma pneumoniae*[a](#tbl3fn1){ref-type="table-fn"}0.79, 0.680.00361*x*219, *x*188  Coronavirus 229E0.95*x*137Coronavirus OC430.550.00692*x*79.80.00700.92Coronavirus NL63ntntCoronavirus HKU1[a](#tbl3fn1){ref-type="table-fn"}ntnt  RSV-A0.88*x*518RSV-B0.900.0017*x*5290.00040.90Rhinovirus[c](#tbl3fn3){ref-type="table-fn"}0.76, 0.75, 0.76, 0.73*x*447, *x*441, *x*447, *x*429  Adenovirus-1,5,6,7,9,10[d](#tbl3fn4){ref-type="table-fn"}0.87, 0.83*x*116, *x*111Bocavirus0.89*x*119K-ras0.830.0075*x*1110.00160.90*Chlamydophila pneumoniae*[a](#tbl3fn1){ref-type="table-fn"}0.73, 0.78*x*107*x*97, *x*104[^11][^12][^13][^14][^15]

A cohort of clinical specimens were tested by both multiplex rtPCR and DNA microarray analysis (*n*  = 50) to assess the performance of the DNA microarray for clinical investigation. The results are summarised in [Table 4](#tbl4){ref-type="table"} and representative images of five typical microarray experiments alongside barplots of hybridisation signals and rtPCR amplification plots are represented in [Fig. 1](#fig1){ref-type="fig"} . Experimental images shown are positive for Parainfluenza-3, *M. pneumoniae*, Influenza A, Influenza B as well as an RSV-A/Rhinovirus co-infection. A total of 20/50 and 25/50 clinical specimens tested positive for a respiratory pathogen(s) using DNA microarray analysis and rtPCR respectively. Positive results of the 50 clinical samples were: four Influenza A (5.6%), three Influenza B (4.2%), three Influenza C (4.2%), one parainfluenza-3 (1.4%), one parainfluenza-4 (1.4%), four human metapneumovirus (5.6%), two *M. pneumoniae* (2.8%), one Coronavirus OC43 (1.4%), one Coronavirus NL63 (1.4%), Coronavirus HKU1 (1.4%), five RSV A (7%) and four Rhinovirus (5.6%). [Table 4](#tbl4){ref-type="table"} illustrates the clinical sensitivity of the DNA microarray-based assay. Real-time PCR *C* ~*t*~ values are listed for all positive specimens alongside DNA microarray results. All six targets not detected by DNA microarray analysis were weakly positive via rtPCR analysis, and had *C* ~*t*~ values \>40 with 4/6 having *C* ~*t*~ values of ≥45. For all of the clinical samples tested, the QSVs were ≥0.60 and had a background of ≤0.10.Table 4DNA microarray analysis of clinical specimens.VirusAT testrtPCRPositivePositive*C*~*t*~ valuesInfluenza A4426.69, 29.41, 34.63, 35.95Influenza B3322.19, 26.76, 36.91Influenza C0345.57[a](#tbl4fn1){ref-type="table-fn"}, 45.74[a](#tbl4fn1){ref-type="table-fn"}, 45.94[a](#tbl4fn1){ref-type="table-fn"}Parainfluenza-30147.16[a](#tbl4fn1){ref-type="table-fn"}Parainfluenza-40140.70[a](#tbl4fn1){ref-type="table-fn"}hMPV4432.61, 32.65, 33.91, 35.07*M. pneumoniae*2236.81, 38.42Coronavirus OC430148.15[a](#tbl4fn1){ref-type="table-fn"}Coronavirus NL630140.02[a](#tbl4fn1){ref-type="table-fn"}Coronavirus HKU10148.79[a](#tbl4fn1){ref-type="table-fn"}RSV A5519.76, 24.93, 27.41, 27.88, 30.36Rhinovirus2429.80, 32.03, 46.65[a](#tbl4fn1){ref-type="table-fn"}, 47.82[a](#tbl4fn1){ref-type="table-fn"}No. of co-infections5Total positive20/2525/2520/50[^16][^17]Fig. 1Examination of clinical samples using spotted DNA microarray analysis. Microarray images, barplots of hybridisation signals and rtPCR amplification curves are shown for five typical samples. Positive hybridisation signals include (A) Parainfluenza-3, (B) *M. pneumoniae*, (C) Influenza A, (D) Influenza B and (E) an RSV-A/Rhinovirus co-infection.

We next attempted to determine the clinical relevance of the findings from the rtPCR and microarray analysis. Only the specimens positive by DNA microarray analysis and with *C* ~*t*~ values \<40 in rtPCR were included in this analysis (*n*  = 17) ([Table 5](#tbl5){ref-type="table"} ). Among these 17 positive test results two patients had a concomitant bacterial respiratory tract infections (*M. pneumoniae*). Antibiotic treatment had been implemented in 13 of the remaining 15 patients and 8 patients had been admitted to hospital. Two patients with an admitting diagnosis of pneumonia and an infiltrate on chest X-ray were positive for *M. pneumoniae* and their antibiotic treatment was therefore considered appropriate. As the majority of other patients neither had an elevated peripheral white cell count nor significant chest X-ray infiltrates, it seems plausible that if a positive viral test result would have been available for clinicians less antibiotics would have been prescribed.Table 5Clinical details of patients with positive throat swab results.AgeSexViral isolateWCCTemperatureCXR infiltrateDiagnosisAdmittedAntibiotic treatment1.61MRSV/Rhino10.736.4NoInf. Exac.YesYes2.97FhMPV9.937NoLRTIYesYes3.76FRSV13.338.7NoLRTIYesYes4.85MFlu B2.936.3NoLRTIYesYes5.88FhMPV17.338.1YesLRTIYesYes6.46FhMPV--37.4NoRTINoYes7.84MhMPV6.536.5YesRTIYesYes8.65FFlu A2.838.1NoRTINoYes9.75F*M. pneum*8.8--YesLRTIYesYes10.67FRSV/Rhino6.936No------11.16FFlu A6.540NoFlu/tonsillitisNoYes12.18M*M. pneum*5.936.3YesLRTINoYes13.23MFlu B2.438.5NoViral illnessNoNo14.77MRSV17.238.5YesLRTIYesYes15.36FFlu A538.2NoInf. Exac.YesYes16.25MFlu A6.438.6NoViral RTINoNo17.21FFlu B13.237.7YesViral RTINoYes[^18]

4. Discussion
=============

Current diagnostic methodologies for the detection of respiratory pathogens are cell culture isolation, antigen/antibody detection and immunofluorescence and conventional/rtPCR. However, not all of these methodologies have the sensitivity, specificity and turnaround time required to have an impact on clinical management. Variations in sample quality may impact on the viability of virus for culture and also the number of available cells for immunofluorescence investigation, whereas PCR is less impacted by poor sample quality. Therefore, molecular techniques are required for an accurate and rapid diagnosis. PCR tests are considered very sensitive, and our data has shown that the combined PCR and DNA microarray-based assay was capable of detecting and identifying 18 pathogens from throat swab specimens in a single run. Our study also shows that the DNA microarray assay for respiratory pathogens has: (i) the sensitivity required for the testing of clinical samples and (ii) the high specificity and capacity to achieve identification and differentiation of a pathogen(s) in a single test in a single working day.

Importantly, the redundant spotting of probes and multiple non-identical probes per target on the array allows a direct intra-assay confirmation of positives. This ability to perform replicate analyses in a single assay run provides a major advantage over real-time technologies that are limited by the number of available dyes and the current detection technology platforms. In addition, precipitation staining utilised in the microarray approach described herein does not have problems with respect to signal stability, quenching effects and cross-talk between detectors which can be encountered with rtPCR. Most importantly, microarrays have a significantly greater multiplexing capability than rtPCR as presently a maximum of five targets can be analysed per well which in best practice would employ one filter for the internal control leaving only four filters to detect pathogens per reaction. In addition, there is increasing concern regarding the accuracy of the multiple formats compared to the amplification in a simplex reaction.

The PCR-based DNA microarray assay failed to detect a number of samples that were reported as weak positives by rtPCR; however these positives with *C* ~*t*~ values \>40 are of dubious clinical significance. This technology allows for differential diagnoses and an advantage of the microarray is that it provides more clinically relevant information. This technology will inevitably impact on the management strategy of respiratory infections and potentially could be employed to limit outbreaks in institutions as well as to decrease empiric antibiotic usage where the pathogen responsible can be shown to be viral. The ability to attach large numbers of probes on each solid phase and the comparatively low cost per pathogen tested of such an oligonucleotide microarray-based assay compared to multiplex rtPCR suggests it may be a potential alternative for clinical testing. Furthermore, the increased capacity of such testing will broaden the approach to diagnosis and patient management. Timely molecular test results can contribute to good antimicrobial stewardship and help prevent secondary complications associated with antibiotic treatment, such as intravenous line infections or potential toxic/allergic side effects. Of the 7 patients with an Influenza A or B positive test result, two had been admitted to general medical wards. The admission of influenza patients into open wards poses a significant infection control hazard as this could potentially result in influenza outbreaks. Molecular testing of respiratory specimens could help initiate appropriate isolation and infection control measures to protect other patients.

To date, high-density spotted DNA microarrays have almost exclusively been used for research purposes for a broad spectrum of applications ([@bib4], [@bib10], [@bib28], [@bib29]). However, this technology is also being employed in the clinical laboratory for diagnosis of viral pathogens in clinical specimens and can potentially become a frontline screening assay supplanting quantitative PCR in the management of herpesvirus and adenoviral infections in the immunocompromised patient population ([@bib20]). While high-density *in situ* synthesised DNA microarrays can offer a greater analytical sensitivity and can accommodate a greater number of probes for a more advanced approach to analysis, e.g. resequencing microarrays ([@bib17]) and genotyping ([@bib18]), low density DNA microarray-based analysis is a cost-effective assay concept. In the future, combining microarray hybridisation with high-throughput, automated DNA extraction and amplification will have a significant impact on high-throughout analysis. Regarding the role of spotted DNA microarrays in diagnostics, we have shown that a suitable low density platform is available for the development of diagnostic assays. Though less sensitive, this may paradoxically be of benefit in the identification of clinically significant levels of pathogen. The cost and ease of automation incorporating liquid handling and multiplexing capability makes this platform an attractive alternative technique for the standardisation purposes required in clinical diagnostics. This is specifically relevant when current commercial assays do not meet the test algorithms for a particular clinical laboratory and this may have an impact on the approach to specimen testing in the clinical laboratory and hospital setting. This will inevitably aid the detection, monitoring and therapeutic treatment of disease. DNA microarray-based analysis may thus be a potential alternative for clinical testing, providing more information on pathogens allowing better assessment of the viral aetiopathogenic agent(s) responsible for respiratory illness in the case viral and bacterial of co-infections.
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[^1]: Probe sequences used for the amplification and labelling of the clinical samples are listed above. All probe sequences were designed in this study or modified from published sequences. NP, nucleoprotein; HN, haemagglutinin-neuraminidase; NCR, non-coding region; NS, non-structural.
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[^10]: Primer sequences and the multiplex set-up for the biotinylation end-point PCR used for labelling of the targets is indicated above. HMPV, human metapneumovirus; RSV, respiratory syncytial virus.

[^11]: Multiplex end-point PCR reactions were set up as above, using known positive samples for the viral and bacterial pathogens. Purified biotinylated PCR products were hybridised to the diagnostic DNA microarray. Signal intensities for all probes along with signal intensities of the internal staining controls are listed above. nt, not tested; QSV, quantitative staining control.

[^12]: 2 probes per virus.

[^13]: 3 probes per virus.

[^14]: 4 probes per virus.

[^15]: 5 probes per virus.

[^16]: Results for the DNA microarray-based analyses of clinical specimens are listed above, along with rtPCR results.

[^17]: *C*~*t*~ values \>40 are equivocal results and are unlikely to be clinically relevant.

[^18]: Clinical details of the 17/50 patients that had a positive test result are shown above. Two viral co-infections (RSV/Rhino) and two bacterial infections (*M. pneum*) were identified. *Abbreviations*: RSV (respiratory syncytial virus), Rhino (Rhinovirus), hMPV (human Metapneumovirus), Flu B (Influenza B), Flu A (Influenza A), *M. pneum* (*Mycoplasma pneumoniae*), Inf. Exac. (infective exacerbation of chronic obstructive pulmonary), LRTI (lower respiratory tract infection), and RTI (respiratory tract infection).
